Effectiveness of Fingolimod spurred the generation of other S1P1 subtype-specific modulators for the treatment of MS, inflammatory bowel disease, psoriasis, and systemic lupus erythematosus25,41–44. This evidence concerns the gene S1PR1 and inflammatory bowel disease.